XML 40 R22.htm IDEA: XBRL DOCUMENT
v3.24.3

Restatement of Previously Issued Financial Statements (Tables) | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2024 | Dec. 31, 2023
Accounting Changes and Error Corrections [Abstract] |  |
Schedule of Error Corrections And Prior Period Adjustments | The impact of the errors described above also impact the Company’s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A. Schedule of Error Corrections And Prior Period Adjustments
Consolidated Balance Sheet as of December 31, 2023 |  | As Reported |  |  | Adjustment |  |  | As Restated |
Additional paid in capital |  |  | 19,543,363 |  |  |  | 9,945,692 |  |  |  | 29,489,055 |
Accumulated deficit |  |  | (15,487,612 | ) |  |  | (9,945,692 | ) |  |  | (25,433,304 | )
| (1) | Adjustments include corrections for stock compensation errors (increase of $7,843,052); recognition of Series A Preferred Stock accrued dividends (decrease of $402,064); correction of issuance cost recognition related to financing transactions (decrease of $174,082); corrections to the Company’s initial classification and recognition of warrants issued in financing transactions (decrease of $416,266), reclassifications of warrants from liability to equity (increase of $881,554); correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $2,213,498).
| (2) | Adjustments include corrections for stock compensation errors (increase of $8,009,461); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $240,930); reversal of accrued Series A Preferred Stock dividends (decrease of $402,064); recognition of bifurcated derivatives and recording of loss at issuance (increase of $296,151); correction of issuance cost recognition related to financing transactions (decrease of $166,407); and the aggregate adjustments to 2022 net loss as detailed below (increase of $1,967,621).
| The impact of the errors described above also impact the Company’s Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2022 within additional paid in capital and accumulated deficit, resulting in the preparation and filing of this Annual Report on Form 10-K/A. Schedule of Error Corrections And Prior Period Adjustments
Consolidated Balance Sheet as of December 31, 2023 |  | As Reported |  |  | Adjustment |  |  | As Restated |
Additional paid in capital |  |  | 19,543,363 |  |  |  | 9,945,692 |  |  |  | 29,489,055 |
Accumulated deficit |  |  | (15,487,612 | ) |  |  | (9,945,692 | ) |  |  | (25,433,304 | )
The following tables summarize the effect of the restatement on each financial statement line item as of the dates indicated:
Consolidated Balance Sheet as of December 31, 2022 |  | As Reported |  |  | Adjustment |  |  | As Restated |
Additional paid in capital |  |  | 16,572,741 |  |  |  | 9,945,692 | (1) |  |  | 26,518,433 |
Accumulated deficit |  |  | (8,894,889 | ) |  |  | (9,945,692 | )(2) |  |  | (18,840,581 | )
| (1) | Adjustments include corrections for stock compensation errors (increase of $7,843,052); recognition of Series A Preferred Stock accrued dividends (decrease of $402,064); correction of issuance cost recognition related to financing transactions (decrease of $174,082); corrections to the Company’s initial classification and recognition of warrants issued in financing transactions (decrease of $416,266), reclassifications of warrants from liability to equity (increase of $881,554); correction in the application of extinguishment accounting upon settlement of debt instruments (increase of $2,213,498).
| (2) | Adjustments include corrections for stock compensation errors (increase of $8,009,461); adjustment of the estimated Series A Preferred Stock warrant obligation fair value (increase of $240,930); reversal of accrued Series A Preferred Stock dividends (decrease of $402,064); recognition of bifurcated derivatives and recording of loss at issuance (increase of $296,151); correction of issuance cost recognition related to financing transactions (decrease of $166,407); and the aggregate adjustments to 2022 net loss as detailed below (increase of $1,967,621).
Consolidated Statement of Operations for the year ended December 31, 2022 |  | As Reported |  |  | Adjustment |  |  | As Restated |
Research and development, net of contract expense reimbursements |  | $ | 1,148,712 |  |  | $ | (101,327 | ) |  | $ | 1,047,385 |
General and administrative |  |  | 538,796 |  |  |  | (65,082 | ) |  |  | 473,714 |
Legal and professional |  |  | 866,770 |  |  |  | (44,043 | ) |  |  | 822,727 |
Net loss from operations |  |  | (2,554,278 | ) |  |  | 210,452 |  |  |  | (2,343,826 | )
Interest expenses |  |  | (917,879 | ) |  |  | 489,191 |  |  |  | (428,688 | )
Financing fee |  |  | — |  |  |  | (189,912 | ) |  |  | (189,912 | )
Change in fair value of derivative liabilities |  |  | — |  |  |  | (189,000 | ) |  |  | (189,000 | )
Change in fair value of warrant liabilities |  |  | 94,025 |  |  |  | (492,700 | ) |  |  | (398,675 | )
Loss on extinguishment of debt |  |  | — |  |  |  | (1,795,652 | ) |  |  | (1,795,652 | )
Net loss |  |  | (3,028,448 | ) |  |  | (1,967,621 | ) |  |  | (4,996,069 | )
Dividend on Series A Preferred Stock |  |  | (71,009 | ) |  |  | (331,055 | ) |  |  | (402,064 | )
Deemed dividend on extinguishment of Series A Preferred Stock |  |  | — |  |  |  | (439,427 | ) |  |  | (439,427 | )
Deemed dividend on modification of equity-classified warrants, as restated |  |  | — |  |  |  | (941,000 | ) |  |  | (941,000 | )
Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated |  |  | — |  |  |  | 31,423 |  |  |  | 31,423 |
Net loss attributable to common stockholders |  |  | (3,099,457 | ) |  |  | (3,647,680 | ) |  |  | (6,747,137 | )
Net loss per shares - basic and diluted |  | $ | (2.32 | ) |  | $ | (2.72 | ) |  | $ | (5.04 | )
Consolidated Statement of Stockholders’ Equity as of December 31, 2022 |  | As Reported |  |  | Adjustment |  |  | As Restated |
Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs |  | $ | — |  |  | $ | 9,951,356 |  |  | $ | 9,951,356 |
Common stock issued for cash |  |  | 10,008,095 |  |  |  | (10,008,095 | ) |  |  | — |
Warrants exercised for cash |  |  | 14,098 |  |  |  | (14,098 | ) |  |  | — |
Warrants issued for financing costs |  |  | 412,241 |  |  |  | (397,579 | ) |  |  | 14,662 |
Common stock issued for conversion of accrued interest |  |  | 588,524 |  |  |  | (588,524 | ) |  |  | — |
Common stock issued upon conversion of convertible debt and exercise of related warrants |  |  | — |  |  |  | 1,199,916 |  |  |  | 1,199,916 |
Common stock issued for exercise of warrants with settlement of notes payable |  |  | 576,476 |  |  |  | 1,576,648 |  |  |  | 2,153,124 |
Stock-based compensation |  |  | 403,956 |  |  |  | (166,409 | ) |  |  | 237,547 |
Dividends on Series A preferred stock |  |  | (71,009 | ) |  |  | (331,055 | ) |  |  | (402,064 | )
Common shares issued for dividends on and conversion of Series A preferred stock |  |  | 402,068 |  |  |  | (4 | ) |  |  | 402,064 |
Reclassification of fair value of warrant liability to equity upon initial public offering |  |  | — |  |  |  | 881,553 |  |  |  | 881,553 |
Net loss |  |  | (3,028,448 | ) |  |  | (1,967,621 | ) |  |  | (4,996,069 | )
Consolidated Statement of Cash Flows for the year ended December 31, 2022 |  | As Reported |  |  | Adjustment |  |  | As Restated |
Net loss |  | $ | (3,028,448 | ) |  | $ | (1,967,621 | ) |  | $ | (4,996,069 | )
Change in fair value of derivative liabilities |  |  | — |  |  |  | 189,000 |  |  |  | 189,000 |
Change in fair value of warrant liabilities |  |  | (94,025 | ) |  |  | 492,700 |  |  |  | 398,675 |
Amortization of debt discount and finance fees |  |  | 885,505 |  |  |  | (508,121 | ) |  |  | 377,384 |
Loss on settlement of convertible debt |  |  | — |  |  |  | 1,795,652 |  |  |  | 1,795,652 |
Fair value of freestanding instruments in excess of proceeds |  |  | — |  |  |  | 189,912 |  |  |  | 189,912 |
Gain on interest relief on conversion of notes payable |  |  | 12,625 |  |  |  | (12,625 | ) |  |  | - |
Stock-based compensation |  |  | 403,956 |  |  |  | (166,409 | ) |  |  | 237,547 |
Accrued interest payable |  |  | (13,177 | ) |  |  | 31,555 |  |  |  | 18,378 |
Net cash used in operating activities |  |  | (2,710,454 | ) |  |  | 44,043 |  |  |  | (2,666,411 | )
Proceeds from issuance of common shares and warrants |  |  | 10,022,193 |  |  |  | (26,680 | ) |  |  | 9,995,513 |
Proceeds from convertible notes payable |  |  | 600,715 |  |  |  | (50,000 | ) |  |  | 550,715 |
Proceeds from notes payable and warrants |  |  | — |  |  |  | 50,000 |  |  |  | 50,000 |
Payment for finance costs related to convertible notes payable |  |  | — |  |  |  | (17,363 | ) |  |  | (17,363 | )
Net cash provided by financing activities |  |  | 10,622,908 |  |  |  | (44,043 | ) |  |  | 10,578,865 |
Supplemental non-cash financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued upon conversion of convertible debt |  | $ | 588,524 |  |  | $ | 611,392 |  |  | $ | 1,199,916 |
Common stock issued for exercise of warrants with settlement of notes payable |  | $ | 576,476 |  |  | $ | 1,576,648 |  |  | $ | 2,153,124 |
Common shares issued for dividends on and conversion of Series A preferred stock |  | $ | 402,068 |  |  | $ | (4 | ) |  | $ | 402,064 |
Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively |  | $ | 412,241 |  |  | $ | (397,579 | ) |  | $ | 14,662 |
Reclassification of fair value of warrant liability to equity upon initial public offering |  | $ | — |  |  | $ | 881,553 |  |  | $ | 881,553 |
Consolidated Balance Sheet as of December 31, 2021 |  | As Reported |  |  | Adjustment |  |  | As Restated |
Additional paid in capital |  |  | 4,150,948 |  |  |  | 7,912,992 | (1) |  |  | 12,063,940 |
Accumulated Deficit |  |  | (5,795,432 | ) |  |  | (8,049,080 | )(2) |  |  | (13,844,512 | )
(1) | Adjustments include adjustment to the carrying value of notes payable, including recognition of day 1 loss (decrease of $7,351); identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of 89,118); and stock compensation adjustments (increase of $8,009,461).
(2) | Adjustments include reversal of dividend liability recorded (decrease of $331,059); identification of deferred IPO costs (decrease of ($55,182); identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of 89,118); adjustment to the estimated fair value of warrant liability (increase of $240,930); adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $274,048); and stock compensation adjustments (increase of $8,009,461).

X
- Definition Schedule Of Error Corrections And Prior Period Adjustments [TableTextBlock] + References No definition available. + Details
Name: | SHPH_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock
Namespace Prefix: | SHPH_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingChangesAndErrorCorrectionsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration